Gene therapy for tissue repair and regeneration

Advanced Drug Delivery Reviews

Volumn 33, Issue 1-2, 1998, Pages 53-69

  Bonadio, Jeffrey ^a   Goldstein, Steven A ^a   Levy, Robert J ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cytokine; Fibroblast; Fracture repair; Gene activated matrix; Granulation tissue; Plasmid gene transfer

Indexed keywords

BONE; GENE TRANSFER; ORTHOPEDICS; TISSUE CULTURE;

BONE REGENERATION; GENE THERAPY;

GENETIC ENGINEERING;

CYTOKINE;

CANCER; CARDIOVASCULAR DISEASE; FRACTURE; GENE THERAPY; GENE TRANSFER; GRANULATION TISSUE; HUMAN; INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE REGENERATION; TISSUE REPAIR;

EID: 0032479766     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00020-9     Document Type: Review

References (185)

1. [1] T. Friedmann, Overcoming the obstacles to gene therapy, Sci. Am. 3 (1997) 96-101.
2. [2] T. Friedmann, Human gene therapy - an immature genie, but certainly out of the bottle, Nat. Med. 2 (1996) 144-147.
3. [3] T. Friedmann, The maturation of human gene therapy, Acta Paediatr. 85 (1996) 1261-1265.
4. [4] S.H. Orkin, A.G. Motulsky, Report and recommendations of the panel to assess the NIH investment in research on gene therapy. http://www.nih.gov/news/panelrep.html> 1995.
5. [5] P.E. Shockett, D.G. Schatz, Diverse strategies for tetracycline-regulated inducible gene expression, Proc. Natl. Acad. Sci. USA 93 (1996) 5173-5176.
6. [6] V.M. Rivera, T. Clackson, S. Natesan, et al., A humanized system for pharmacologic control of gene expression, Nat. Med. 2 (1996) 1028-1032.
7. [7] J.R. Morgan, Y. Barrandon, H. Green, R.C. Mulligan, Expression of an exogenous growth hormone gene by transplantable human epidermal cells, Science 237 (1987) 1476-1479.
8. [8] J.M. Wilson, R.C. Mulligan, A.D. Callow, P. Libby, R.N. Salomon, L.K. Birinyi, Implantation of vascular grafts lined with genetically modified endothelial cells, Science 244 (1989) 1344-1346.
9. [9] J.A. Wolff, J.K. Yee, H.F. Skelly, et al., Expression of retrovirally transduced genes in primary cultures of adult rat hepatocytes, Proc. Natl. Acad. Sci. USA 84 (1987) 3344-3348.
10. [10] F.D. Ledley, G.J. Darlington, T. Hahn, S.L. Woo, Retroviral gene transfer into primary hepatocytes: implications for genetic therapy of liver-specific functions, Proc. Natl. Acad. Sci. USA 84 (1987) 5335-5339.
11. [11] J.M. Wilson, N.R. Chowdhury, M. Grossman, et al., Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes, Proc. Natl. Acad. Sci. USA 87 (1990) 8437-8441.
12. [12] T.D. Palmer, R.A. Hock, W.R. Osborne, A.D. Miller, Efficient retrovirus-mediated transfer and expression of a human adenosine deaminase gene in diploid skin fibroblasts from an adenosine deaminase-deficient human, Proc. Natl. Acad. Sci. USA 84 (1987) 1055-1059.
13. [13] R.I. Garver, A. Chytil, M. Courtney, R.G. Crystal, Clonal gene therapy: transplanted mouse fibroblast clones express human α1-antitrypsin gene in vivo, Science 237 (1987) 762-764.
14. [14] D.S. Anson, R.A. Hock, D. Austen, et al., Towards gene therapy for hemophilia B, Mol. Biol. Med. 4 (1987) 11-20.
15. [15] M.B. Rosenberg, T. Friedmann, R.C. Robertson, et al., Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression, Science 242 (1988) 1575-1578.
16. [16] R.M. Blaese, K.W. Culver, A.D. Miller, et al., T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years, Science 270 (1995) 475-480.
17. [17] B. Lim, J.F. Apperley, S.H. Orkin, D.A. Williams, Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells, Proc. Natl. Acad. Sci. USA 86 (1989) 8892-8896.
18. [18] E. Barr, J.M. Leiden, Systemic delivery of recombinant proteins by genetically modified myoblasts, Science 254 (1991) 1507-1509.
19. [19] J. Dhawan, L.C. Pan, G.K. Pavlath, M.A. Travis, A.M. Lanctot, H.M. Blau, Systemic delivery of human growth hormone by injection of genetically engineered myoblasts, Science 254 (1991) 1509-1512.
20. [20] J.R. Haynes, D.E. McCabe, W.F. Swain, G. Widera, J.T. Fuller, Particle-mediated nucleic acid immunization, J. Biotechnol. 44 (1996) 37-42.
21. [21] D.-C. Tang, M. DeVit, S.A. Johnston, Genetic immunization is a simple method for eliciting an immune response, Nature 356 (1992) 152-154.
22. [22] J.A. Wolff, R.M. Malone, P. Williams, et al., Direct gene transfer into mouse muscle in vivo, Science 247 (1990) 14651468.
23. [23] J.A. Wolff, Naked DNA transport and expression in mammalian cells, Neuromuscul. Disord. 7 (1997) 314-318.
24. [24] J.A. Norman, P. Hobart, M. Manthorpe, P. Felgner, C. Wheeler, Development of improved vectors for DNA-based immunization and other gene therapy applications, Vaccine 15 (1997) 801-803.
25. [25] P.L. Felgner, Nonviral strategies for gene therapy, Sci. Am. 276 (1997) 102-106.
26. [26] R.I. Mahato, A. Rolland, E. Tomlinson, Cationic lipid-based gene delivery systems: pharmaceutical perspectives, Pharm. Res. 14 (1997) 853-859.
27. [27] E. Mathiowitz, J.S. Jacob, Y.S. Jong, et al., Biologically erodable microspheres as potential oral drug delivery systems, Nature 386 (1997) 410-414.
28. [28] V. Labhasetwar, C. Song, R.J. Levy, Nanoparticle drug delivery system for restenosis, Adv Drug Deliv Rev 24 (1997) 63-85.
29. [29] S.S. Davis, Biomedical applications of nanotechnology - implications for drug targeting and gene therapy, Trends Biotechnol. 15 (1997) 217-224.
30. 165 in patients with ischaemic limb, Lancet 348 (1996) 370-374.
31. [31] J. Bonadio, E. Smiley, S.A. Goldstein, K. Ciftci, V. Labhasetwar, R.J. Levy, Direct gene transfer in vivo using the GAM technology. Cold Spring Harbor Gene Therapy Meeting, Cold Spring Harbor, NY, September 25-29, 1996.
32. [32] J. Fang, Y.-Y. Zhu, E. Smiley, et al., Stimulation of new bone formation by direct transfer of osteoinductive plasmid genes, Proc. Natl. Acad. Sci. USA 93 (1996) 5753-5758.
33. [33] T. Ferkol, J.C. Perales, F. Mularo, R.W. Hanson, Receptor-mediated gene transfer into macrophages, Proc. Natl. Acad. Sci. USA 93 (1996) 101-105.
34. [34] M.S. Wadhwa, W.T. Collard, R.C. Adami, D.L. McKenzie, K.G. Rice, Peptide-mediated gene delivery: influence of peptide structure on gene expression, Bioconj. Chem. 8 (1997) 81-88.
35. [35] C. Plank, B. Oberhauser, K. Mechtler, C. Koch, E. Wagner, The influence of endosome-disruptive peptides on gene transfer using synthetic cirus-like gene transfer systems, J. Biol. Chem. 269 (1994) 12918-12924.
36. [36] W.S. Casscells, D.A. Lappi, B.B. Olwin, et al., Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors, Proc. Natl. Acad. Sci. USA 89 (1992) 7159-7163.
37. [37] B.A. Sosnowski, A.M. Gonzalez, L.A. Chandler, Y.J. Buechler, G.F. Pierce, A. Baird, Targeting DNA to cells with basic fibroblast growth factor (FGF2), J. Biol. Chem. 271 (1996) 33647-33653.
38. [38] D.S. Goldfarb, J. Bariegy, G. Schoolnik, R. Kornberg, Synthetic peptides as nuclear localization signals, Nature 322 (1986) 641-644.
39. [39] S. Connelly, M. Kaleko, Gene therapy for hemophilia A, Thromb. Haemost. 78 (1997) 31-36.
40. [40] J.C. Marini, N.L. Gerber, Osteogenesis imperfecta. Rehabilitation and prospects for gene therapy, J. Am. Med. Assoc. 277 (1997) 746-750.
41. [41] C. Lengauer, B. Vogelstein, K.W. Kinzler, Genetic instability in colorectal cancers, Nature 386 (1997) 623-627.
42. [42] I. Tomlinson, M. Novelli, M. Ilyas, Molecular genetics of colon cancer, Cancer Metastasis Rev. 16 (1997) 67-79.
43. [43] R.M. Blaese, Gene therapy for cancer, Sci. Am. 276 (1997) 111-115.
44. [44] G. Dranoff, E. Jaffee, A. Lazenby, et al., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity, Proc. Natl. Acad. Sci. USA 90 (1993) 3539-3543.
45. [45] S.A. Rosenberg, P. Aebersold, K. Cornetta, et al., Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction, New Engl. J. Med. 323 (1990) 570-578.
46. [46] J.R. Bischoff, D.H. Kirn, A. Williams, et al., An adenovirus mutant that replicates selectively in p53-deficient human tumor cells, Science 274 (1996) 373-376.
47. [47] T. Licht, I. Pastan, M.M. Gottesman, F. Herrmann, In vivo drug-selectable genes: a new concept in gene therapy, Stem Cells 15 (1997) 104-111.
48. [48] B.L. Davidson, E.D. Allen, K.F. Kozarsky, J.M. Wilson, B.J. Roessler, A model system for in vivo gene transfer into the central nervous system using an adenoviral vector, Nat. Genet. 3 (1993) 219-223.
49. [49] R. Ross, The pathogenesis of atherosclerosis: a perspective for the 1990s, Nature 362 (1993) 801-809.
50. [50] P.W. Serruys, P. DeJaegere, F. Kiemeneij, et al., A comparison of balloon-expandable-stent implantation with balloon angioplasty with coronary artery disease, New Engl. J. Med. 331 (1994) 489-495.
51. [51] D.L. Fischman, M.B. Leon, D.S. Baim, et al., A randomized comparison of coronary-stent-placement and balloon angioplasty in the treatment of coronary artery disease, New Engl. J. Med. 331 (1994) 496-501.
52. [52] Y. Tsurumi, S. Takeshita, D. Chen, et al., Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion, Circulation 94 (1996) 3281-3290.
53. [53] A.W. Clowes, Vascular gene therapy in the 21st century, Thromb. Haemost. 78 (1997) 605-610.
54. [54] M. Simons, E.R. Edelman, J.-L. DeKeyser, R. Langer, R.D. Rosenberg, Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo, Nature 359 (1992) 67-70.
55. [55] D.W. Muller, D. Gordon, H. San, et al., Catheter-mediated pulmonary vascular gene transfer and expression, Circ. Res. 75 (1994) 1039-1049.
56. [56] B.A. French, W. Mazur, N.M. Ali, et al., Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine arteries, atherosclerotic arteries, and two models of coronary restenosis, Circulation 90 (1994) 2402-2413.
57. [57] R.J. Guzman, E.A. Hirschowitz, S.L. Brody, R.G. Crystal, S.E. Epstein, T. Finkel, In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene, Proc. Natl. Acad. Sci. USA 91 (1994) 1648-1656.
58. [58] T. Ohno, D. Gordon, H. San, et al., Gene therapy for vascular smooth muscle cell proliferation after arterial injury, Science 265 (1994) 781-784.
59. [59] M.W. Chang, E. Barr, S. Jonathan, et al., Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product, Science 267 (1995) 518-522.
60. [60] C. Indolfi, E.V. Avvedimento, A. Rapacciuolo, et al., Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury, Nat. Med. 1 (1995) 541-545.
61. [61] A.H. Schulick, K.D. Newman, R. Virmani, D.A. Dicheck, In vivo gene transfer into injured carotid arteries. Optimization and evaluation of acute toxicity, Circulation 91 (1995) 2407-2414.
62. [62] M.W. Chang, E. Barr, M.M. Lu, K. Barton, J.M. Leiden, Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21, inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty, J. Clin. Invest. 95 (1995) 2260-2268.
63. [63] E. Heiko, V.D. Leyen, G.H. Gibbons, et al., Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene, Proc. Natl. Acad. Sci. USA 92 (1995) 1137-1141.
64. [64] R.L. Harrell, S. Rajanayagam, A.M. Doanes, et al., Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase, Circulation 96 (1997) 621-627.
65. [65] G. Leclerc, D. Gal, S. Takeshita, S. Nikol, L. Weir, J.M. Isner, Percutaneous arterial gene transfer in a rabbit model: efficiency in normal and balloon-dilated atherosclerotic arteries, J. Clin. Invest. 90 (1992) 936-944.
66. [66] R. Riessen, H. Rahimizadeh, E. Blessing, S. Takeshita, J.J. Barry, J.M. Isner, Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon, Hum. Gene Ther. 4 (1993) 749-758.
67. [67] E.G. Nabel, L. Shum, V.J. Pompili, et al., Direct transfer of TGF beta 1 gene into arteries stimulates fibrocellular hyperplasia, Proc. Natl. Acad. Sci. USA 90 (1993) 10759-10763.
68. [68] J.M. Isner, K. Walsh, J.F. Symes, et al., Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease, Circulation 91 (1995) 2687-2692.
69. 165 gene transfer, Circulation 94 (1996) 3291-3302.
70. [70] J.M. Isner, The role of angiogenic cytokines in cardiovascular disease, Clin. Immunol. Immunopathol. 80 (1996) S82-S91.
71. [71] S. Takeshita, L. Weir, L.P. Zheng, et al., Biochem. Biophys. Res. Commun. 1350 (1997) 80-88.
72. [72] J.M. Isner, Angiogenesis for revascularization of ischemic tissues, Eur. Heart J. 18 (1997) 1-2.
73. [73] A.W. Clowes, Improving the interface between biomaterials and the blood. The gene therapy approach, Circulation 93 (1996) 1319-1320.
74. 165 inhibits thrombus formation and intimal thickening, J. Am. Coll. Cardiol. 29 (1997) 1371-1379.
75. [75] C.J. Magovern, C.A. Mack, J. Zhang, et al., Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector, Ann. Thorac. Surg. 62 (1996) 425-433.
76. [76] R.A. Morgan, Gene therapy for HIV infection, Clin. Exp. Immunol. 1 (1997) 41-44.
77. [77] C.K. Goldman, D.T. Curiel, J.A. Campain, et al., Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor, Cancer Res. 57 (1997) 1447-1451.
78. [78] G. Palu, Combined strategies for gene therapy of AIDS, Gene Ther. 4 (1997) 179-180.
79. [79] "First trial" of anti-HIV gene therapy [news]. Nature 388 (1997) 510.
80. [80] W.A. Marasco, Intrabodies: turning the humoral immune system outside in for intracellular immunization, Gene Ther. 4 (1997) 11-15.
81. [81] H. Blau, P. Khavari, Gene therapy: progress, problems, prospects, Nat. Med. 3 (1997) 612-612.
82. [82] J.M. Wilson, Adenoviruses as gene-delivery vehicles, New Engl. J. Med. 334 (1996) 1185-1187.
83. [83] J.M. Wilson, Vectors - shuttle vehicles for gene therapy, Clin. Exp. Immunol. 107(Suppl. 1) (1997) 31-32.
84. [84] Y. Yang, F.A. Nines, K. Berencsi, E.E. Furth, E. Gonczol, J.M. Wilson, Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy, Proc. Natl. Acad. Sci. USA 91 (1994) 4407-4411.
85. [85] Y. Yang, Q. Su, J.M. Wilson, Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs, J. Virol. 70 (1996) 7209-7212.
86. [86] S.K. Tripathy, H.B. Black, E. Goldwassere, J.M. Leiden, Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors, Nat. Med. 2 (1996) 545-550.
87. [87] T. Dobner, N. Horikoshi, S. Rubenwolf, T. Shenk, Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor, Science 272 (1996) 1470-1473.
88. [88] A.M. Kreig, A.-E. Yi, S. Matson, et al., CpG motifs in bacterial DNA trigger direct B-cell activation, Nature 374 (1995) 546-549.
89. [89] Y. Sato, M. Roman, H. Tighe, et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization, Science 273 (1996) 352-354.
90. [90] J.B. Ulmer, J.J. Donnelly, S.E. Parker, G.H. Rhodes, P.L. Felgner, V.J. Dwarki, S.H. Gromkowski, R.R. Deck, C.M. DeWitt, A. Friedman, L.A. Hawe, K.R. Leander, D. Martinez, H.C. Perry, J.W Shiver, D.L. Montgomery, M.A. Liu, Heterologous protection against influenza by injection of DNA encoding a viral protein, Science 259 (1993) 1745-1749.
91. [91] J.J. Donnelly, A. Friedman, D. Martinez, et al., Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus, Nat. Med. 1 (1995) 583-587.
92. [92] J.J. Harrington, G. Van Bokkelen, R.W. Mays, K. Gustashaw, H.F. Willard, Formation of de novo centromeres and construction of first-generation human artificial microchromosomes, Nat. Genet. 15 (1997) 345-355.
93. [93] T. Marcel, J.D. Grausz, The TMC worldwide gene therapy enrollment report, end 1996, Hum. Gene Ther. 8 (1997) 775-800.
94. [94] M. Grossman, S.E. Raper, K. Kozarsky, et al., Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia, Nat. Genet. 6 (1994) 335-341.
95. [95] M. Grossman, D.J. Rader, D.W. Muller, et al., A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia, Nat. Med. 1 (1995) 1148-1154.
96. [96] B.R. Grubb, R.J. Pickles, H. Ye, et al., Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans, Nature 371 (1994) 802-806.
97. [97] K.D. Newman, P.F. Dunn, J.W. Owens, et al., Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia, J. Clin. Invest. 96 (1995) 2955-2965.
98. [98] M.R. Knowles, K.W. Hohneker, Z. Zhou, et al., A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis, New Engl. J. Med. 333 (1995) 823-831.
99. [99] J.F. Bonadio, P.H. Byers, Subtle structural alterations in the chains of type I procollagen produce osteogenesis imperfecta type II, Nature 316 (1985) 363-366.
100. [100] J. Bonadio, T.L. Saunders, E. Tsai, et al., Transgenic mouse model of the mild dominant form of osteogenesis imperfecta, Proc. Natl. Acad. Sci. USA 87 (1990) 7145-7149.
101. [101] R.L. Cruess, in: C.A. Rockwood, D.P. Green (Eds.), Fractures in Adults, Lippincott, Philadelphia, PA, 1984, pp. 147-159.
102. [102] J. Goulet, D. Templemann, Delayed union and nonunion of tibial shaft fractures, Instr. Course Lect. 46 (1997) 281-291.
103. [103] A. Velazco, L.L. Fleming, Open fractures of the tibia treated with the Lottes nail, J. Bone Jt. Surg. 65A (1983) 879-885.
104. [104] A. Preamer, S. Furner, D.P. Rice, in: Musculoskeletal Conditions of the United States, The American Academy of Orthopedic Surgeons, Park Ridge, IL, 1992, pp. 85-124.
105. [105] J.A. Buckwalter, T.A. Einhorn, M.E. Bolander, R.L. Cruess, Healing of the musculoskeletal tissues, in: C.A. Rockwood, D.P. Green, R.W. Bucholz, J.D. Heckman (Eds.), Rockwood and Green's Fractures in Adults, Lippincott-Raven, Philadelphia, PA, 1996, pp. 261-304.
106. [106] T.A. Einhorn, Enhancement of fracture-healing, J. Bone Jt. Surg. 77A (1996) 940-956.
107. [107] S.T. Hansen, The type-IIIC tibial fracture: salvage or amputation, J. Bone Jt. Surg. 69A (1987) 799-800.
108. [108] J.P. Simon, M. Hoogmartens, The value of posterolateral bone-grafting for non-union of the tibia, Acta Orthop. Belg. 50 (1984) 557-564.
109. [109] B.B. Blick, R.J. Brumback, R. Lakatos, et al., Early prophylactic bone grafting of high-energy tibial fractures, Clin. Orthop. 240 (1989) 21-41.
110. [110] F. Behrens, T.H. Comfort, K. Searls, F. Denis, J.T. Young, Unilateral external fixation for severe open tibial fractures: preliminary report of a prospective study, Clin. Orthop. 178 (1983) 111-120.
111. [111] N.A. Peppas, R. Langer, New challenges in biomaterials, Science 263 (1994) 1715-1719.
112. [112] A.H. Heuer, D.J. Fink, V.J. Laraia, et al., Innovative materials processing strategies; a biomimetic approach, Science 255 (1992) 1098-1105.
113. [113] S. Stevenson, N. Cunningham, J. Toth, D. Davy, A.H. Reddi, The effect of osteogenin (a bone morphogenetic protein) on the formation of bone in orthotopic segmental defects in rats, J. Bone Jt. Surg. 76A (1994) 1676-1687.
114. [114] A.W. Ham, A histological study of the early phases of bone repair, J. Bone Jt. Surg. 12 (1930) 827-844.
115. [115] A. Erlebacher, E.H. Filvaroff, S.E. Gitelman, R. Derynck, Toward a molecular understanding of skeletal development, Cell 80 (1995) 371-378.
116. [116] S.E. Harris, M. Sabatini, M.A. Harris, J.Q. Feng, J. Wozney, G.R. Mundy, Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells, J. Bone Miner. Res. 9 (1994) 389-394.
117. [117] K.M. Lyons, R.W. Pelton, B.L.M. Hogan, Patterns of expression of murine Vgr-1 and BMP-2a RNA suggest that transforming growth factor-beta-like genes coordinately regulate aspects of embryonic development, Genes Dev. 3 (1989) 1657-1668.
118. [118] K.M. Lyons, R.W. Pelton, B.L.M. Hogan, Organogenesis and pattern formation in the mouse: RNA distribution patterns suggest a role for bone morphogenetic protein-2A (BMP-2A), Development 109 (1990) 833-844.
119. [119] C.M. Jones, K.M. Lyons, B.L. Hogan, Involvement of bone morphogenetic protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse, Development 111 (1991) 531-542.
120. [120] A. Yamaguchi, T. Katagiri, T. Ikeda, et al., Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro, J. Cell Biol. 113 (1991) 681-687.
121. [121] M. Ahrens, T. Ankenbauer, D. Schroder, A. Hollnagel, H. Mayer, G. Gross, Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro, J. Bone Miner. Res. 12 (1993) 871-880.
122. [122] S.E. Gitelman, M.S. Kobrin, J.-Q. Ye, A.R. Lopez, A. Lee, R. Derynck, Recombinant Vgr-1/BMP-6-expressing tumors induce fibrosis and endochondral bone formation in vivo, J. Cell Biol. 126 (1994) 1595-1609.
123. [123] V. Rosen, J. Nove, J.J. Song, R.S. Thies, K. Cox, J.M. Wozney, Responsiveness of clonal limb bud cell lines to bone morphogenetic protein 2 reveals a sequential relationship between cartilage and bone cell phenotypes, J. Bone Miner. Res. 9 (1994) 1759-1768.
124. [124] T. Katagiri, A. Yamaguchi, M. Komaki, et al., Responsiveness of clonal limb bud cell lines to bone morphogenetic protein 2 reveals a sequential relationship between cartilage and bone cell phenotypes, J. Cell Biol. 127 (1994) 1755-1766.
125. [125] A.H. Reddi, Bone and cartilage differentiation, Curr. Opin. Genet. Dev. 4 (1994) 737-744.
126. [126] T. Nakase, S. Nomura, H. Yoshikawa, et al., J. Bone Miner. Res. 9 (1994) 651-659.
127. [127] E. Ozkaynak, D.C. Rueger, E.A. Drier, et al., EMBO J. 9 (1990) 2085-2093.
128. [128] T.K. Sampath, J.C. Maliakal, P.V. Hauschka, et al., J. Biol. Chem. 267 (1992) 20352-20362.
129. [129] S.D. Cook, G.C. Baffes, M.W. Wolfe, T.K. Sampath, D.C. Rueger, T.S. Whitecloud, J. Bone Jt. Surg. 76A (1994) 827-838.
130. [130] M. Centrella, M.C. Horowitz, J.M. Wozney, T.L. McCarthy, Endocr. Rev. 15 (1994) 27-38.
131. [131] D.R. Sumner, T.M. Turner, A.F. Purchio, W.R. Gombotz, R.M. Urban, J.O. Galante, J Bone Jt. Surg. 77A (1995) 1135-1147.
132. [132] A.B. Roberts, M.B. Sporn, The transforming growth factor-betas, in: M.B. Sporn, A.B. Roberts (Eds.), Peptide Growth Factors and Their Receptors, Handbook of Experimental Pharmacology, Springer-Verlag, Heidelberg, 1990, pp. 419-472.
133. [133] W. Yin, E. Smiley, J. Germiller, et al., Isolation of a novel latent TGF-β binding protein gene (LTBP-3), J. Biol. Chem. 270 (1995) 10147-10160.
134. [134] J. Fang, X. Li, E. Smiley, U. Francke, R.P. Mecham, J. Bonadio, Mouse latent TGF-β binding protein-2: molecular cloning and developmental expression, Biochim. Biophys. Acta. (1997) in press.
135. [135] M.M. Shull, I. Ormsby, A.B. Kier, et al., Nature 359 (1992) 693-699.
136. [136] A.B. Kulkarni, C.-H. Huh, D. Becker, et al., Proc. Natl. Acad. Sci. USA 90 (1993) 770-774.
137. [137] W.V. Giannobile, Periodontal tissue engineering by growth factors, Bone 19(1 Suppl) (1996) 23S-37S.
138. [138] M. Urist, Bone formation by autoinduction, Science 150 (1965) 893-899.
139. [139] R. Langer, J.P. Vacanti, Tissue engineering, Science 260 (1993) 920-925.
140. [140] J.P. Vacanti, C.A. Vacanti, in: R. Lanza, R. Langer, W. Chick (Eds.), Textbook of Tissue Engineering, Landes, Philadelphia, PA, 1997, pp. 1-5.
141. [141] J.P. Vacanti, C.A. Vacanti, in: R. Lanza, R. Langer, W. Chick (Eds.), Textbook of Tissue Engineering, Landes, Philadelphia, PA, 1997, pp. 619-631.
142. [142] L.E. Freed, G. Vunjak-Novakovic, R. Langer, Cultivation of cell-polymer cartilage implants in bioreactors, J. Cell Biochem. 51 (1993) 257-264.
143. [143] L.E. Freed, J.C. Marquis, A. Nohria, J. Emmanual, A.G. Mikos, R. Langer, Neocartilage formation in vitro and in vivo using cells cultured on synthetic biodegradable polymers, J. Biomed. Mater. Res. 27 (1993) 11-23.
144. [144] L.E. Freed, G. Vunjak-Novakovic, R.J. Biron, et al., Biodegradable polymer scaffolds for tissue engineering, Biotechnology 12 (1994) 689-693.
145. [145] L.E. Freed, D.A. Grande, Z. Lingbin, J. Emmanual, J.C. Marquis, R. Langer, Joint resurfacing using allograft chondrocytes and synthetic biodegradable polymer scaffolds, J. Biomed. Mater. Res. 28 (1994) 891-899.
146. [146] P.X. Ma, B. Schloo, D. Mooney, R. Langer, Development of biomechanical properties and morphogenesis of in vitro tissue engineered cartilage, J. Biomed. Mater. Res. 29 (1995) 1587-1595.
147. [147] S. Neher, H.A. Breinan, A. Ramappa, et al., Canine chondrocytes seeded in type I and type II collagen implants investigated in vitro, J. Biomed. Mater. Res. 38 (1997) 95-104.
148. [148] R.K. Khouri, B. Koudsi, A.H. Reddi, Tissue transformation into bone in vivo, J. Am. Med. Assoc. 266 (1991) 1953-1955.
149. [149] A.I. Caplan, S.P. Bruder, in: R. Lanza, R. Langer, W. Chick (Eds.), Textbook of Tissue Engineering, Landes, Philadelphia, PA, 1997, pp. 603-618.
150. [150] C.A. Vacanti, R. Langer, B. Schloo, J.P. Vacanti, Synthetic polymers seeded with chondrocytes provide a template for new cartilage formation, Plast. Reconstr. Surg. 88 (1991) 753-759.
151. [151] L.G. Cima, J.P. Vacanti, C.A. Vacanti, D. Ingber, D. Mooney, R. Langer, Tissue engineering by cell transplantation using degradable polymer substrates, J. Biomech. Eng. 113 (1991) 143-151.
152. [152] W.S. Kim, J.P. Vacanti, L. Cima, et al., Cartilage engineered in predetermined shapes employing cell transplantation on synthetic biodegradable polymers, Plast. Reconstr. Surg. 94 (1994) 233-237.
153. [153] W.C. Puelacher, D. Mooney, R. Langer, J. Upton, J.P. Vacanti, C.A. Vacanti, Design of nasoseptal cartilage replacements synthesized from biodegradable polymers and chondrocytes, Biomaterials 15 (1994) 774-778.
154. [154] W.C. Puelacher, S.W. Kim, J.P. Vacanti, B. Schloo, D. Mooney, C.A. Vacanti, Tissue-engineered growth of cartilage: the effect of varying the concentration of chondrocytes seeded onto synthetic polymer matrices, Int. J. Oral Maxillofac. Surg. 23 (1994) 49-53.
155. [155] K.T. Paige, L.G. Cima, M.J. Yaremchuk, B.L. Schloo, J.P. Vacanti, C.A. Vacanti, De novo cartilage generation using calcium alginate-chondrocyte constructs, Plast. Reconstr. Surg. 97 (1996) 168-178.
156. [156] A.J. Grodzinsky, R.D. Kamm, D.A. Lauffenberger, Quantitative aspects of tissue engineering: basic issues in kinetics, transport and mechanics, in: R. Lanza, R. Langer, W. Chick (Eds.), Textbook of Tissue Engineering, Landes, Philadelphia, PA, 1997, pp. 193-207.
157. [157] D.W. Dempster, F. Cosman, M. Parisien, V. Shen, R. Lindsay, Anabolic actions of parathyroid hormone on bone: update 1995, Endocr. Rev. 4 (1995) 247-250.
158. [158] D.W. Dempster, F. Cosman, M. Parisien, V. Shen, R. Lindsay, Anabolic actions of parathyroid hormone on bone, Endocr. Rev. 14 (1993) 690-709.
159. [159] J. Reeve, D. Williams, R. Hesp, et al., Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis, Lancet 1 (1976) 1035-1038.
160. [160] C.S. Tam, J.N. Heersche, T.M. Murray, J.A. Parsons, Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration, Endocrinology 110 (1982) 506-512.
161. [161] J.M. Hock, I. Gera, J. Fonseca, L.G. Raicz, Human parathyroid hormone (1-34) increases bone mass in ovariectomized and orchidectomized rats, Endocrinology 122 (1988) 2899-2904.
162. [162] M. Gunness-Hey, J.M. Hock, Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats, Bone 10 (1989) 447-452.
163. [163] J.M. Hock, J. Fonseca, M. Gunness-Hey, B.E. Kemp, T.J. martin, Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) and PTH 1-34 on bone in rats, Endocrinology 125 (1993) 2022-2027.
164. [164] J.M. Hock, J. Fonseca, Anabolic effect of human parathyroid hormone (1-34) depends on growth hormone, Endocrinology 127 (1990) 1804-1810.
165. [165] E. Canalis, T.L. McCarthy, M. Centrella, Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrP) on bone collagen synthesis, Endocrinology 126 (1990) 1806-1812.
166. [166] L. Mosekilde, C.H. Sogaard, C.C. Danielsen, O. Toring, M.H.L. Nilsson, The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biochemical testing: a comparison study between hPTH (1-34) and hPTH (1-84), Endocrinology 129 (1991) 421-428.
167. [167] E.C. Weir, G. Terwilliger, L. Sartori, K.L. Insogna, Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo, Calcif. Tissue Int. 51 (1992) 30-34.
168. [168] D.B. Kimmel, R.P. Bozzato, K.A. Kronis, et al., The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats, Endocrinology 132 (1993) 1577-1584.
169. [169] H. Oxlund, C. Ejersted, T.T. Andreassen, O. Torring, M.H.L. Nilsson, Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum, Calcif. Tissue Int. 53 (1993) 394-399.
170. [170] R.H. Rixon, J.F. Whitfield, L. Gagnon, et al., Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase, J. Bone Miner. Res. 9 (1994) 1179-1189.
171. [171] J.S. Finkelstein, A. Klibanski, E.H. Schaefer, M.D. Hornstein, I. Schiff, R.M. Neer, Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency, New Engl. J. Med. 331 (1994) 1618-1623.
172. [172] S. Nishida, A. Yamaguchi, T. Tanizawa, et al., Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation or proliferation and differentiation of osteoprogenitor cells in bone marrow, Bone 15 (1994) 717-723.
173. [173] D. Leaffer, M. Sweeney, L.A. Kellerman, et al., Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone related peptide and bovine PTH 1-34, Endocrinology 136 (1995) 3624-3631.
174. [174] V. Shen, R. Birchman, R. Xu, et al., Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats, J. Clin. Invest. 96 (1995) 2331-2338.
175. [175] T. Sone, M. Fukunaga, S. Ono, T. Nishiyama, A small dose of human parathyroid hormone (1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis, Miner. Electrolyte Metab. 21 (1995) 232-235.
176. [176] P. Watson, D. Lazowski, V. Han, L. Fraher, B. Steer, A. Hodsman, Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor-1 gene expression in ovariectomized rats, Bone 16 (1995) 357-365.
177. [177] H. Dobnig, R.T. Turner, Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by inactivation of bone lining cells, Endocrinology 136 (1995) 3632-3638.
178. [178] N.E. Lane, D.B. Kimmel, M.H.L. Nilsson, et al., Bone selective analogs of human PTH 1-34 increase bone formation in an ovariectomized rat model, J. Bone Miner. Res. 11 (1996) 614-625.
179. [179] J.F. Whitfield, P. Morley, G.E. Willick, et al., Comparison of the ability of recombinant human parathyroid hormone, rhPTH 1-84, and hPTH 1-34 to stimulate femoral trabecular bone growth in ovariectomized rats, Calcif. Tissue Int. 60 (1997) 26-29.
180. [180] N.C. Partridge, S.R. Bloch, A.T. Pearman, Signal transduction pathways mediating parathyroid hormone regulation of osteoblastic gene expression, J. Cell Biochem. 55 (1994) 321-327.
181. [181] T.J. Martin, E.H. Allan, S. Fukumoto, J.M. Moseley, Some aspects of the anabolic action of parathyroid hormone, Miner. Electrolyte Metab. 21 (1995) 87-90.
182. [182] H. Juppner, A.B. Abou-Samra, M. Freeman, et al., A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide, Science 254 (1991) 1024-1026.
183. [183] G.V. Segre, Receptors for parathyroid hormone and parathyroid hormone-related protein, in: J.P. Bilezikian, L.G. Raicz, G.A. Rodan (Eds.), Principles of Bone Biology, Academic Press, San Diego, CA, 1996, pp. 377-403.
184. [184] T.B. Usdin, C. Gruber, T.I. Bonner, Identification and functional characterization of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor, J. Biol. Chem. 270 (1995) 15455-15459.
185. [185] P.C. Kao, C.S. Grant, G.G. Klee, S. Khosla, Clinical performance of parathyroid hormone immunometric assays, Mayo Clin. Proc. 67 (1992) 637-645.